Cefazolin prophylaxis is associated with lower surgical site infection risk than vancomycin following elective spine surgery

IF 3.2 Q3 Medicine
North American Spine Society Journal Pub Date : 2026-03-01 Epub Date: 2026-02-08 DOI:10.1016/j.xnsj.2026.100857
Michael S. Kim MD, Melissa R. Romoff BA, Ryan Beyer MD, Emily Tse BA, Hao-Hua Wu MD, Don Y. Park MD, Yu-Po Lee MD, Nitin Bhatia MD, Sohaib Hashmi MD, Emily S. Mills
{"title":"Cefazolin prophylaxis is associated with lower surgical site infection risk than vancomycin following elective spine surgery","authors":"Michael S. Kim MD,&nbsp;Melissa R. Romoff BA,&nbsp;Ryan Beyer MD,&nbsp;Emily Tse BA,&nbsp;Hao-Hua Wu MD,&nbsp;Don Y. Park MD,&nbsp;Yu-Po Lee MD,&nbsp;Nitin Bhatia MD,&nbsp;Sohaib Hashmi MD,&nbsp;Emily S. Mills","doi":"10.1016/j.xnsj.2026.100857","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Surgical site infection (SSI) remains a major cause of morbidity following elective spine surgery, with incidence rates up to 3%. Current guidelines recommend cefazolin as the first-line prophylactic antibiotic due to its efficacy against methicillin-sensitive <em>Staphylococcus aureus</em> (MSSA) and coagulase-negative staphylococci (CoNS). However, reported B-lactam allergies are commonly cited in clinical practice as a reason for substitution with vancomycin, which provides inferior coverage for MSSA and limited gram-negative activity. Prior single center studies suggest higher SSI risk with vancomycin, but large-scale evidence remains limited.</div></div><div><h3>Methods</h3><div>A retrospective cohort analysis was conducted using the TriNetX US Collaborative Network (2015-2023). Adults undergoing elective spine surgery, including transforaminal or posterior interbody fusion (TLIF/PLIF), multilevel lumbar fusion, posterior cervical fusion, anterior cervical discectomy and fusions (ACDF), and microdiscectomy, were identified. Patients receiving perioperative cefazolin or vancomycin within 24 hours of surgery were included. 1:1 propensity score matching controlled for demographics, comorbidities, and infection risk factors. The primary outcome was 90-day SSI, assessed using ICD-10 diagnosis codes. Risk ratios (RR) were estimated using Cox proportional hazards models.</div></div><div><h3>Results</h3><div>After matching, 12,996 patients were included across 5 procedure cohorts. Cefazolin prophylaxis was associated with lower or comparable SSI risk compared with vancomycin across all procedures. Statistically significant differences were observed for TLIF/PLIF (0.82% vs. 2.30%; RR 0.36, 95% CI 0.18–0.7; p = .0019) and microdiscectomy (0.34% vs. 0.69%; RR 0.50, 95% CI 0.27–0.93; p = .025). Nonsignificant trends favored cefazolin for posterior cervical fusion (0.88% vs. 1.41%), multilevel lumbar fusion (1.25% vs. 1.51%), and ACDF (0.30% vs. 0.54%).</div></div><div><h3>Conclusions</h3><div>Cefazolin prophylaxis is associated with significantly lower SSI risk in elective spine procedures. These findings support cefazolin as the preferred perioperative antibiotic and emphasize the need for accurate B-lactam allergy assessment to optimize infection prevention and antimicrobial stewardship in spine surgery.</div></div>","PeriodicalId":34622,"journal":{"name":"North American Spine Society Journal","volume":"25 ","pages":"Article 100857"},"PeriodicalIF":3.2000,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"North American Spine Society Journal","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666548426000119","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/2/8 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Surgical site infection (SSI) remains a major cause of morbidity following elective spine surgery, with incidence rates up to 3%. Current guidelines recommend cefazolin as the first-line prophylactic antibiotic due to its efficacy against methicillin-sensitive Staphylococcus aureus (MSSA) and coagulase-negative staphylococci (CoNS). However, reported B-lactam allergies are commonly cited in clinical practice as a reason for substitution with vancomycin, which provides inferior coverage for MSSA and limited gram-negative activity. Prior single center studies suggest higher SSI risk with vancomycin, but large-scale evidence remains limited.

Methods

A retrospective cohort analysis was conducted using the TriNetX US Collaborative Network (2015-2023). Adults undergoing elective spine surgery, including transforaminal or posterior interbody fusion (TLIF/PLIF), multilevel lumbar fusion, posterior cervical fusion, anterior cervical discectomy and fusions (ACDF), and microdiscectomy, were identified. Patients receiving perioperative cefazolin or vancomycin within 24 hours of surgery were included. 1:1 propensity score matching controlled for demographics, comorbidities, and infection risk factors. The primary outcome was 90-day SSI, assessed using ICD-10 diagnosis codes. Risk ratios (RR) were estimated using Cox proportional hazards models.

Results

After matching, 12,996 patients were included across 5 procedure cohorts. Cefazolin prophylaxis was associated with lower or comparable SSI risk compared with vancomycin across all procedures. Statistically significant differences were observed for TLIF/PLIF (0.82% vs. 2.30%; RR 0.36, 95% CI 0.18–0.7; p = .0019) and microdiscectomy (0.34% vs. 0.69%; RR 0.50, 95% CI 0.27–0.93; p = .025). Nonsignificant trends favored cefazolin for posterior cervical fusion (0.88% vs. 1.41%), multilevel lumbar fusion (1.25% vs. 1.51%), and ACDF (0.30% vs. 0.54%).

Conclusions

Cefazolin prophylaxis is associated with significantly lower SSI risk in elective spine procedures. These findings support cefazolin as the preferred perioperative antibiotic and emphasize the need for accurate B-lactam allergy assessment to optimize infection prevention and antimicrobial stewardship in spine surgery.
选择性脊柱手术后使用头孢唑林预防手术部位感染的风险比使用万古霉素低
手术部位感染(SSI)仍然是择期脊柱手术后发病的主要原因,发生率高达3%。目前的指南推荐头孢唑林作为一线预防性抗生素,因为它对甲氧西林敏感的金黄色葡萄球菌(MSSA)和凝固酶阴性葡萄球菌(con)有效。然而,在临床实践中,报告的b -内酰胺过敏通常被引用为万古霉素替代的原因,万古霉素对MSSA的覆盖范围较低,革兰氏阴性活性有限。先前的单中心研究表明万古霉素有较高的SSI风险,但大规模证据仍然有限。方法采用TriNetX美国协作网络(2015-2023)进行回顾性队列分析。接受选择性脊柱手术的成人,包括经椎间孔或后路椎间融合术(TLIF/PLIF)、多节段腰椎融合术、颈椎后路融合术、颈椎前路椎间盘切除术和融合术(ACDF)以及微椎间盘切除术。纳入围手术期24小时内接受头孢唑林或万古霉素治疗的患者。1:1倾向评分匹配控制了人口统计学、合并症和感染危险因素。主要终点为90天SSI,使用ICD-10诊断代码进行评估。采用Cox比例风险模型估计风险比(RR)。结果匹配后,12996例患者被纳入5个手术队列。在所有程序中,与万古霉素相比,头孢唑林预防与较低或相当的SSI风险相关。TLIF/PLIF的差异有统计学意义(0.82% vs. 2.30%; RR 0.36, 95% CI 0.18-0.7; p = 0.0019)和微椎间盘切除术(0.34% vs. 0.69%; RR 0.50, 95% CI 0.27-0.93; p = 0.025)。头孢唑林在颈椎后路融合(0.88% vs. 1.41%)、腰椎多节段融合(1.25% vs. 1.51%)和ACDF (0.30% vs. 0.54%)中的应用趋势不显著。结论:选择性脊柱手术中,头孢唑林预防可显著降低SSI风险。这些发现支持头孢唑林作为围手术期首选抗生素,并强调需要准确的b -内酰胺过敏评估,以优化脊柱外科感染预防和抗菌药物管理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.80
自引率
0.00%
发文量
71
审稿时长
48 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书